Research Triangle Park, N.C., USA, 13th August 2019 / AskBio, the world’s foremost clinical stage and gene therapy platform company, has acquired Synpromics, the leader in gene control synthetic promoter technology, bioinformatics and intelligent data-driven design that enables more precise cell targeting and gene expression. Synpromics will operate as a wholly owned subsidiary and remain headquartered in Edinburgh, United Kingdom.
Synpromics joined the BSGCT in Sheffield at the end of June to share the latest progress in gene and cell therapy. The Annual Meeting kicked off to a great start with a welcome networking reception, sponsored by Synpromics, held in the beautiful Winter Garden. This provided an excellent opportunity to catch up with current and possible future collaborators.
The Synpromics team at the BSGCT Annual Meeting
David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York. Watch David's presentation below or view the pdf here.